Researchers at the Katholieke Universiteit in Leuven, Belgium have joined forces with two French pharmaceutical companies to discover new compounds targeting the LRRK2 gene in Parkinson’s disease. ---Subscribe to MedNous to access this article--- Research & University News Finance, Grants, Deals Company News
